1National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing
2Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. M-27A. NCCLS,1997
3Mock M, Monod M, Baudraz-Rosselet F, et al. Tinea capitis dermatophytes: susceptibility to antifungal drugs tested in vitro and in vivo, Dermatology, 1998;197(4): 361 -367
4Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing practical aspects and current challenges. Clin Microbiol Rev, 2001 ;14(4):643 - 658
5DW, Radford SA, Oakley KL, et al. Correlation between in vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother, 1997 ;40 (3) : 401 - 414
6Espinel-ingroff A, comparison of the E-test with the NCCLS M38- P method for antifungal susceptibility testing of common and emerging pathogenic filament formation of fungi. J Clin Microbiol, 2001 ;39(4) : 1360
7Espinel-ingroff A, Dawson K, Pfaller H et al. Comparative and collaborative evaluation of standardization antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother,1995 ;39: 314 -9
8Espinel-ingroff A, Bowden R, Meneses P et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing for59 ; 139-43
9Rex J, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoins for antifungal susceptibility testing:conceptual frame- work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis, 1997 ;24:235-7
10espinel-ingroff, F. Barehiesi, K. C. Hazeen Standardization of antifungal susceptibility testing and clinical relevance Medical Mycology 1998, 36,supplement 1, 68 - 78
